JNCI Correction Revisits How Stored FFPE Tissue Affects Next-Generation Sequencing
A correction tied to a Journal of the National Cancer Institute article draws attention back to a problem molecular pathologists know well: formalin-fixed paraffin-embedded tissue does not remain biologically static over time. As archived specimens sit in storage, nucleic acid quality can deteriorate, and the downstream effect may be seen when laboratories attempt next-generation sequencing on material that once seemed perfectly usable. The corrected title itself captures the core message with unusual clarity — long-term storage can impair sequencing performance, while a DNA repair enzyme may help restore enough integrity for analysis.
For cancer genomics, this is not an abstract technical issue. Tumor profiling often depends on archived FFPE blocks, especially when the original biopsy is small, the disease course is long, or treatment decisions arise years after tissue collection. Sequencing failure in that setting can delay targeted therapy decisions, complicate biomarker interpretation, or force a repeat biopsy that may be difficult or unsafe to obtain. In everyday pathology practice, the age and preservation history of the specimen can matter just as much as the assay platform running the test.
One sentence captures the practical consequence: old tissue can still look usable under the microscope while proving molecularly fragile at the bench.
Why Archived Tissue Becomes a Molecular Problem
FFPE preservation remains indispensable because it stabilizes morphology and allows routine histopathology. Yet fixation chemistry comes with a price. Formalin introduces crosslinks and other modifications that can interfere with extraction and amplification of DNA, and those problems can deepen as storage time increases. Over time, the sample may accumulate additional damage, leaving shorter fragments, altered bases, and a more challenging template for sequencing workflows that depend on clean amplification and accurate readout.
For clinicians and laboratorians, the implication is direct: a tumor block can be diagnostically reliable for histology but increasingly unreliable for genomics. When sequencing quality drops, the issue may not be the platform, the bioinformatic pipeline, or the operator. The specimen itself may have crossed a threshold where archival value remains but molecular fidelity has eroded.
The correction’s wording places restoration with a DNA repair enzyme at the center of the message, suggesting that damaged FFPE-derived DNA is not necessarily beyond rescue. That concept has immediate relevance for oncology laboratories working with older blocks, particularly when the alternative is losing access to a potentially actionable genomic result. Enzymatic repair strategies are attractive because they target the pre-analytic problem directly rather than forcing laboratories to accept degraded DNA as fixed input.
Sequencing Failure Has Direct Clinical Consequences
In precision oncology, a failed assay is rarely just a laboratory inconvenience. It can mean missing a targetable alteration, losing confidence in a negative result, or requiring another tissue procurement in a patient who may already be frail. In tumors where treatment choice hinges on molecular status, even modest losses in sequencing performance can translate into slower decisions and narrower options.
The corrected title also reflects a broader reality in translational cancer research: pre-analytic handling is not a minor technicality. Sample age, fixation, and storage conditions all shape whether a specimen can support modern molecular diagnostics. As sequencing becomes more embedded in routine care, laboratories need workflows that anticipate degradation rather than react to it after a specimen has already failed.
A damaged archive can still answer the histology question and fail the genomics question.
What the Correction Adds to the Literature Trail
A correction notice does not usually expand the scientific record with new cohorts, new endpoints, or new statistical claims. Its value lies elsewhere: it restores precision to the message the article is meant to carry. Here, the corrected title reinforces two linked ideas — long-term FFPE storage can worsen sequencing performance, and a DNA repair enzyme may improve recoverability. For readers in pathology, molecular diagnostics, and oncology, that is enough to keep the paper clinically relevant even in the absence of detailed abstract data in the feed itself.
The topic also fits a growing operational need in cancer centers and reference laboratories. Many institutions hold vast FFPE archives, and those banks are increasingly mined for retrospective genomics, companion diagnostics, and translational research. The longer those blocks sit unused, the greater the chance that molecular yield will suffer. A repair step that salvages material after storage could extend the usable life of archived tissue and reduce the number of specimens discarded as technically inadequate.
Still, the correction notice leaves essential practical questions unanswered in the feed: which storage intervals were most affected, how much sequencing performance declined, which genomic readouts benefited most from repair, and whether the restored DNA translated into clinically reliable calls across different assays. Those details matter for implementation, but they are not supplied here and should not be assumed.
Laboratory Stewardship and the Limits of Archival Tissue
This correction sits at the intersection of pathology workflow and cancer genomics stewardship. It serves as a reminder that archived tissue is not a passive reservoir but a biologic substrate subject to time-dependent decay. The longer a block remains on the shelf, the more laboratories may need to consider molecular preservation strategies, specimen triage, and repair-based preparation before sequencing begins.
For oncologists, pathologists, and laboratory directors, the central lesson is straightforward: the age of a specimen can influence the confidence of the genomic result as much as the tumor type itself. In the setting of FFPE tissue, molecular quality control is not optional. It is part of the diagnostic chain that determines whether sequencing can still guide care.
The correction does not provide the full experimental detail needed to change practice on its own. It does, however, keep attention fixed on a real vulnerability in cancer testing: the slow biochemical erosion of stored tissue and the possibility that enzymatic repair may partially reverse it.